Nicox SA, an international ophthalmology company, has confirmed its eligibility for the PEA-PME scheme for the upcoming year. This confirmation allows investors to continue to include the company's shares in this tax scheme dedicated to small and medium-sized stocks.
Nicox has assessed its eligibility criteria for the PEA-PME according to the provisions set by the monetary and financial code. The company's shares, listed on Euronext Growth Paris (ticker: ALCOX), retain their eligibility status for the upcoming year, offering investors the same tax advantages as the classic PEA scheme.
Innovative Ophthalmic Solutions
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Nicox is developing innovative solutions in the field of eye health. The group notably has NCX 470, an eye drop in advanced development phase aimed at reducing intraocular pressure in patients with glaucoma, licensed to international partners. Nicox also markets VYZULTA® in the United States and across 15 other territories, as well as ZERVIATE® for allergic conjunctivitis in several markets.
Nicox a significativement renforcé sa position financière en 2025.
Risks mentioned
Baisse potentielle de la demande pour les nouveaux produits.
Risque de retard dans les soumissions réglementaires.
Opportunities identified
Soumission prévue de la NDA de NCX 470 aux États-Unis en été 2026.
Initiation du programme clinique de phase 3 pour NCX 470 au Japon.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
